Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $21.79 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.